Alkermes may separate oncology business, says CEO

Alkermes has said it is considering a spin-out of its cancer business into an independent, publicly-traded company, retaining its traditional focus on neurosciences.

After FDA approval, Alkermes plans soft launch for antipsych...

The FDA approval of Alkermes' new antipsychotic drug Lybalvi couldn't have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly ge

Alkermes bolts on Rodin Therapeutics to bulk up thin pipelin...

Alkermes rebuffed by FDA on antidepressant

Alkermes is facing a significant delay for its ALKS 5461 candidate for major depressive disorder after the FDA turned down its marketing application.

Alkermes/Biogen hope for less tummy trouble with new MS pill

Alkermes and Biogen have filed a new multiple sclerosis pill with the FDA, which they hope will treat the disease with fewer unpleasant gastrointestinal side effects than the big pharma’s o

Alkermes preps filing for weight-friendly schizophrenia drug

Alkermes is planning to head to the FDA next year with a new schizophrenia drug that, according to phase III data, could sidestep one of the main side effects of other drugs.